Reducing Clinical and Staff Burnout with AI Automation
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Wisconsin radiopharmaceuticals company Cellectar raises $2.7M for cancer treatments
Cellectar Inc. has raised $2.7 million for its radiopharmaceutical technology that treats and detects a variety of cancers, according to a regulatory filing. The company's lead compound is currently in Phase 1 clinical trials for cancer treatment.
Wisconsin’s Cellular Dynamics amends regulatory filing, now says it has raised $40M
Another day, another dollar -- or rather a few million dollars -- for pluripotent stem cell company Cellular Dynamics Inc. After filing a regulatory document last week with the Securities and Exchange Commission stating it had raised $31 million, the Wisconsin company amended the filing. The company now has raised $40.6 million in equity, according to a new document.
The Funding Model for Cancer Innovation is Broken — We Can Fix It
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Cellular Dynamics of Wisconsin raises $31M for pluripotent stem-cell technology
Stem cell company Cellular Dynamics International Inc. has received a staggering $31 million investment, according to a filing with the Securities and Exchange Commission. The company specializes in pluripotent stem cells, which can differentiate into any cell type for use in drug development.
Wisconsin’s Rapid Diagnostek gets $1.5M investment for biosensor technology
Rapid Diagnostek is developing a handheld sensor that can be used to detect diseases, bacteria or viruses by sampling a patient's or animal's urine, saliva or blood.
Wisconsin trade group BioForward names new executive director
Board members want Renk to increase membership, boost political and purchasing clout, and expand on programs such as jobs fairs and educational initiatives.
Boston’s Flex BioMedical follows $1 million to Wisconsin
Flex is developing a polymer-based joint lubricant to reduce pain and increase mobility in osteoarthritis patients. It's meant to replace hyaluronic acid injection treatments that in many cases keep pain away for six months to a year, but in some cases don't work at all. They want to be in clinical trials no later than 2011.
presented by
Transforming Patient Care: The Role of AI-Powered Assistants
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Oncology drugmaker ProCertus closes on $2.1 million
The oncology drugmaker also said Tuesday it has started enrolling patients in a clinical trial to test whether its drug, DermX, can prevent radiodermatitis, a skin inflammation caused by radiation therapy. It's also developing ProDermaCel, which prevents hair loss, and OralX, which protects against radiation-induced inflammation on the digestive tract.